Evidence map›Paper›PMID 30529638›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2019

Development and evaluation of a BK polyomavirus serotyping assay using Luminex technology.

Herman F Wunderink, Caroline S de Brouwer, Els van der Meijden, Diana V Pastrana, Aloysius C M Kroes, Christopher B Buck, Mariet C W Feltkamp

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Herman F WunderinkDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: H.F.Wunderink@umcutrecht.nl.
Caroline S de BrouwerDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Els van der MeijdenDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Diana V PastranaLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892-4263, USA.
Aloysius C M KroesDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Christopher B BuckLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892-4263, USA.
Mariet C W FeltkampDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Leiden University Medical Center · NLNational Cancer Institute · US

Funding

BKV and JCV vaccine developmentZIABC011460 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BUCK, CHRISTOPHER · 2012 to 2025
$7.8M
Intramural NIH HHS ZIA BC011460
6 · The paper itself

Abstract

backgroundThe BK polyomavirus (BKPyV) is subdivided into four genotypes. The consequences of each genotype and of donor-recipient genotype (mis)match for BKPyV-associated nephropathy (BKPyVAN) in kidney transplant recipients (KTRs) are unknown.

objectivesTo develop and evaluate a genotype-specific IgG antibody-based BKPyV serotyping assay, in order to classify kidney transplant donors and recipients accordingly. STUDY

designVP1 antigens of six BKPyV variants (Ib1, Ib2, Ic, II, III and IV) were expressed as recombinant glutathione-s-transferase-fusion proteins and coupled to fluorescent Luminex beads. Sera from 87 healthy blood donors and 39 KTRs were used to analyze seroreactivity and serospecificity against the different BKPyV genotypes. Six sera with marked BKPyV serotype profiles were analyzed further for genotype-specific BKPyV pseudovirus neutralizing capacity.

resultsSeroreactivity was observed against all genotypes, with seropositivity rates above 77% comparable for KTRs and blood donors. Strong cross-reactivity (r > 0.8) was observed among genotype I subtypes, and among genotypes II, III and IV. Seroresponses against genotypes I and IV seemed genuine, while those against II and III could be out(cross)competed. GMT (Luminex) and IC

conclusionsDespite some degree of cross-reactivity, this serotyping assay seems a useful tool to identify the main infecting BKPyV genotype within a given individual. This information, which cannot be obtained otherwise from nonviremic/nonviruric individuals, could provide valuable information regarding the prevalent BKPyV genotype in kidney donors and recipients and warrants further study.

Indexed as

Antibodies, ViralBK VirusCross ReactionsGenotypeHumansImmunoassayImmunoglobulin GKidney TransplantationPolyomavirus InfectionsSerogroupSerotypingTransplant RecipientsTumor Virus InfectionsAntibodies, ViralImmunoglobulin GBK polyomavirusGenotypesKidney transplantationSerotypes

Identifiers

PMID30529638
PMCPMC8136301
OpenAlexW2902001246

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.